Citations

Clear

3484 citation(s) found for "Sy, Sarah".

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Othman, Tamer , Roloff, Gregory W. , Miller, Katharine, Zhang, Amy , Sutherland, Katherine C. , Faramand, Rawan , Hill, LaQuisa C. , Jeyakumar, Nikeshan , Ladha, Abdullah , Kopmar, Noam E., Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Solh, Melhem , Guzowski, Caitlin, Tan, Virginia, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul , Mountjoy, Luke, Schwartz, Marc S., Connor, Matthew P. , Vasu, Sumithira, Kumaran, Muthu, Hoeg, Rasmus T., Tracy, Sean , Yaghmour, George , Pullarkat, Vinod , Muffly, Lori , Aldoss, Ibrahim, Jeyakumar, Nikeshan , Ladha, Abdullah , Sasine, Joshua , Lin, Chenyu , Hilal, Talal , Majhail, Navneet S , Dykes, Kaitlyn C , Logan, Aaron C , Connor, Matthew , Cassaday, Ryan D , Leonard, Jessica T , Shah, Bijal , Frey, Noelle V , Muffly, Lori , Hill, LaQuisa C , Faramand, Rawan , Sutherland, Katherine , Roloff, Gregory W , Othman, Tamer , Zhang, Amy , Muhsen, Ibrahim N. , Sasine, Joshua , Lin, Chenyu , Kopmar, Noam E. , Tsai, Stephanie, Hilal, Talal , Majhail, Navneet S. , Battiwalla, Minoo , Malik, Shahbaz A. , Mountjoy, Luke , Dykes, Kaitlyn C. , Wang, Jiasheng , Vasu, Sumithira , Hoeg, Rasmus T. , Yalniz, Fevzi , Cassaday, Ryan D. , Shah, Bijal , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020707 | PMID 42349018 Get It

Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.
The “Brain's Traffic Map” Reveals Neural Pathways Linked to Coronary Microvascular Dysfunction in Women
Has, Arzu Ceylan , Wertheimer, Jeffrey , Wei, Janet , Xie, Yibin , Li, Debiao , Dumitrașcu, Oana , Kremen, Sarah , Tan, Zaldy S. , Nelson, Michael D. , Has Silemek, Arzu C , Wertheimer, Jeffrey C , Gonzales, Mitzi , Li, Debiao , Dumitrascu, Oana M , Kremen, Sarah , Tan, Zaldy S , Nelson, Micheal D , Bairey Merz, C Noel , Sati, Pascal , Gao, Wei , Wei, Janet , Gonzales, Mitzi M. , Merz, C. Noel Bairey

Mayo Clinic

Brain and Behavior | June 25, 2026 | Volume: 16 | Issue: 6 | Pages: No page available

10.1002/brb3.71559 | PMID 42348298 Get It

ABSTRACT Background The brain–heart axis is central to vascular health, yet no imaging biomarkers capture integrated dysfunction across neural and coronary microvascular networks. Although coronary microvascular dysfunction links to cognitive decline, neural correlates connecting cerebral efficiency with coronary physiology remain unclear. Objectives To determine whether the Unified Structural and Functional Connectivity (USFC)—a multimodal magnetic resonance imaging (MRI) “traffic map” of brain network efficiency—predicts coronary endothelial function and cognition in women with ischemia and no obstructive coronary artery disease (INOCA). Methods Thirty‐three women with suspected INOCA from the Women's Ischemia Syndrome Evaluation (WISE) study (NCT03876223) underwent invasive coronary function testing, cardiac MRI, cognitive evaluation, and multimodal brain MRI. USFC, structural connectivity (SC), and functional connectivity (FC) were computed for predefined 10 backbone pathways. Support vector regression and logistic classification assessed predictive performance. Results USFC explained 16%–20% more variance in coronary endothelial function, myocardial perfusion reserve, and cognition than SC or FC alone ( p < 0.05). Connectivity between the left caudate–superior medial orbital gyrus and right calcarine–inferior occipital gyrus emerged as robust predictors of crystallized cognition ( r = –0.78, p FDR < 0.05) and coronary endothelial function ( r = 0.70, p FDR < 0.05), respectively. USFC also best discriminated low versus high coronary blood flow (area under the ROC curve [AUC]: USFC 0.622 vs. SC 0.349 and FC 0.425; p < 0.05). Conclusions USFC identifies neuro–cardiac pathways linking cerebral efficiency with coronary endothelial function. These results introduce a sensitive biomarker of systemic vulnerability, highlighting occipital and frontostriatal pathways as shared substrates of dysfunction. USFC offers a mechanistic framework for detecting vascular risk across metabolically demanding tissues. Trial Registration ClinicalTrials.gov identifier: NCT03876223
Accuracy of the rapid‐response electroencephalography's Automated Seizure Burden Estimator: A follow‐up validation study of version 8 ( AccuRASE II )
Sheikh, Zubeda , Fong, Michael W K , Dhakar, Monica B. , Fang, Wei , Ayub, Neishay , Bacic, Janine , Haider, Hiba A. , Foreman, Brandon , Gilmore, Emily J. , Mizrahi, Moshe , Osman, Gamaleldin , Sheikh, Zubeda B , Dhakar, Monica B , Molino, Janine , Karakis, Ioannis , Schmitt, Sarah E , Osman, Gamaleldin , Yoo, Ji Yeoun , Hirsch, Lawrence J , Haider, Hiba A , Ayub, Neishay , Gilmore, Emily , Foreman, Brandon , Karakis, Ioannis , Yoo, Ji Yeoun , Hirsch, Lawrence J.

Mayo Clinic

Epilepsia | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70352 | PMID 42347801 Get It

Abstract Objective Ceribell Inc.'s point‐of‐care electroencephalographic (EEG) system and artificial intelligence‐based Automated Seizure Burden Estimator (ASBE; ClarityPro) have US Food and Drug Administration clearance for diagnosing electrographic status epilepticus (ESE). The AccuRASE study using ASBE version 6 (V6) showed high negative predictive value (NPV) but limited sensitivity and positive predictive value (PPV) at certain thresholds. Version 8 (V8) is the updated algorithm trained with additional EEG samples. Methods We tested V8 on the previously used rapid‐response EEG test dataset (not used to train V8). Sensitivity, specificity, PPV, and NPV were compared against blinded expert annotations. ESE, ESE and possible ESE (ESE/pESE), electrographic seizures (ESz), and Esz with highly epileptiform patterns (Esz/HEPs) at burden thresholds of >1%, >10%, >20%, >50%, and >90% were analyzed. Additionally, we evaluated the built‐in ESE and ESE/pESE alerts (≥90% over 5 min, ≥20% over 1 h, or ≥10 continuous minutes of seizure). Results V8 showed 100% sensitivity at lower thresholds (>10%–20%) for ESE (V6 .86), without a specificity loss (V8 .9 vs. V6 .85), and retained NPV (V8 1.0 vs. V6 .99). Sensitivity at 50% threshold was .86 for ESE (V6 .71), and specificity was .94 (V6 .91); PPV for ESE was 30% for ESE and 80% for ESE/pESE. The specificity for ESE remained high for 90% burden (V8 .96, V6 .97) but the sensitivity dropped (.29 vs. V6 .43). Sensitivity was lower for ESz/HEPs (.54 → .44 at >10% threshold), although the algorithm is not designed to detect HEPs. Built‐in alert analysis showed significantly improved sensitivity for ESE (.57 → .86); specificity and NPV remained high (>.94). Significance ASBE V8 showed meaningful improvements in sensitivity, continued excellent NPV, and improved built‐in alert accuracy for ESE and ESE/pESE. The best seizure burden threshold for ruling out ESE now is 20% (vs. 10% with V6) and that for ruling in ESE/pESE with reasonable certainty is 50% (vs. 90% with V6).
Abstract PR004: BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials
Sievers, Quinlan, Lu, Hao, Cool, Allison , Grajewski, Stefan, Kong, Tim , Noviski, Mark, Mukerji, Ratul , Iuliano, James, Ye, Jordan , Rios, Mateo Sanchez Garcia de los, Bousquet, Hugo , Whelan, Sarah , Tan, May, Phelps, Christopher, Raman, Jahan, Notti, Ryan, Navarrete, Lizbeth Mendoza, Sekeres, Samantha, Lamkin, Eria, Bravo, Eduardo , Ewalt, Mark, Islam, Prioty , Mato, Anthony, Roeker, Lindsey, Taylor, Justin, Thompson, Meghan, Hansen, Gwenn, Abdel-Wahab, Omar, Sievers, Quinlan , Noviski, Mark , Mi, Xiaoli , Ficici, Emel , Iuliano, James N , Bousquet, Hugo, Notti, Ryan Q , Ewalt, Mark D. , Mato, Anthony R. , Roeker, Lindsey E. , Hansen, Gwenn M , Abdel‐Wahab, Omar

Mayo Clinic

Blood Cancer Discovery | June 24, 2026 | Volume: 7 | Issue: 3_Supplement | Pages: PR004-PR004

10.1158/2643-3249.lymphoma26-pr004 Get It

Abstract Early-phase clinical trials of BTK degraders in relapsed/refractory CLL have shown response rates of over 80%, including in patients with BTK mutations that confer resistance to conventional BTK inhibitors (BTKi). The molecular basis of resistance to BTK degraders is unknown and, given the promise of this class of drugs, would hold implications for therapy sequencing and the design of next-generation BTK degraders. To this end we identified five patients at Memorial Sloan Kettering who developed progressive disease while being treated on the phase 1 trials of zelebrudomide (NCT04830137, 4 patients) or bexobrutideg (NCT05131022, 1 patient). In two patients, one treated with zelebrudomide and the other with bexobrutideg, a pre-existing BTK A428D mutation had expanded at progression, rising from &lt;1.5% at the start of treatment to &gt;25%. In both cases, the increase in frequency of BTK A428D coincided with the loss of BTK degradation in peripheral blood B cells. No mutation in cereblon, the ligase utilized by these BTK degraders, was detected. To validate these clinical findings we generated wild-type and BTK A428D knock-in single-cell clones in TMD8 and HBL1 cells. BTK A428D conferred resistance to BTKi, including ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib, as well as the clinical-stage BTK degraders zelebrudomide, bexobrutideg, BGB-16673, and AbbVie-1 (Compound 1, WO 2023183811). BTK A428D’s pan-resistance is unique compared to previously studied BTKi resistance mutations which remain susceptible to at least one BTKi and all clinical-stage BTK degraders tested. To understand how BTK A428D confers pan-resistance to BTKi and BTK degraders we conducted surface plasmon resonance studies which demonstrated that BTKi and all four clinical-stage BTK degraders tested are unable to bind BTK A428D. We next solved the crystal structure of apo BTK A428D to 1.8Å, which revealed that the mutant aspartate, which is larger and negatively charged compared to the wild-type alanine, sterically blocks BTKi and degraders from accessing residues in the hinge region of the kinase that are required for drug binding. We next asked why BTK A428D, despite conferring pan-resistance, has only been detected in 1.1% of patients treated with BTK inhibitors. Intriguingly, we noted that in one of our index patients, the frequency of BTK A428D declined and became undetectable after the withdrawal of zelebrudomide, suggesting a fitness defect. To assess this hypothesis, we compared the proliferation rates of five TMD8 wild-type and five BTK A428D single-cell clones; the BTK A428D clones grew more slowly and were consistently outcompeted in mixing studies. In summary, low-frequency BTK A428D mutations can expand under the selection pressure of BTK degraders and confer clinical resistance by preventing drug binding. The mutation, however, is outcompeted in the absence of BTK-targeted therapies. These findings provide rationale for the investigation of combination therapies and the development of next-generation BTK degraders capable of circumventing BTK A428D. Citation Format: Quinlan Sievers, Hao Lu, Allison Cool, Stefan Grajewski, Tim Kong, Mark Noviski, Xiaoli Mi, Emel Ficici, Ratul Mukerji, James Iuliano, Jordan Ye, Mateo Sanchez Garcia de los Rios, Hugo Bousquet, Sarah Whelan, May Tan, Christopher Phelps, Jahan Raman, Ryan Notti, Lizbeth Mendoza Navarrete, Samantha Sekeres, Eria Lamkin, Eduardo Bravo, Mark Ewalt, Prioty Islam, Anthony Mato, Lindsey Roeker, Justin Taylor, Meghan Thompson, Gwenn Hansen, Omar Abdel-Wahab. BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr PR004.
Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritis
Karpouzas, George , González‐Gay, Miguel Á. , Pascual‐Ramos, Virginia , Misra, Durga Prasanna , Rantapää‐Dahlqvist, Solbritt , Sfikakis, Petros , Dessein, Patrick , Hitchon, Carol A, Galarza-Delgado, D. Á. , Riel, Piet Van, Hauge, Ellen M., Kitas, George D, Karpouzas, George Athanasios , Myasoedova, Elena , Rantapää-Dahlqvist, Solbritt , Dessein, Patrick , Galarza-Delgado, Dionicio Angel , Semb, Anne Grete , Gonzalez-Gay, Miguel A , Misra, Durga Prasanna , Myasoedova, Elena , Dessein, Patrick H , Hitchon, Carol , Semb, Anne Grete , Hauge, Ellen‐Margrethe , Ormseth, Sarah R.

Mayo Clinic

RMD Open | June 24, 2026 | Volume: 12 | Issue: 2 | Pages: e006929

10.1136/rmdopen-2026-006929 | PMID 42342284 Get It

Objectives Rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) are linked to disease activity, severity and cardiovascular risk in rheumatoid arthritis (RA). Since RA-related inflammation associates with cardiovascular disease, we investigated whether RF and ACPA status influence the relationship between RA activity and event risk. Methods We assessed 3952 cardiovascular disease-free patients with prevalent RA registered in an international observational consortium between 1985 and 2012. Main outcome was a first major adverse cardiovascular event (MACE) including myocardial infarction, stroke and cardiovascular death. Follow-up accrued from enrolment until first MACE or censoring. Multivariable Cox models stratified by centre risk evaluated disease activity, RF, ACPA and their interactions. Results We recorded 184 first MACE events over 22 981 patient-years. Disease activity associated with MACE (HR 1.18 (95% CI 1.03 to 1.35)), whereas RF (HR 1.26 (0.82 to 1.94)) and ACPA (HR 1.25 (0.85 to 1.83)) did not reach statistical significance, though CIs were wide and a clinically meaningful association cannot be excluded. A three-way interaction between disease activity, RF and ACPA on MACE (p for interaction=0.044) was observed. RA activity associated with MACE in seronegative and double seropositive (p≤0.047), but not single RF-positive or ACPA-positive patients. Among RF-negative participants, RA activity was linked to MACE in ACPA-negative but not positive ones (p for interaction=0.003). Among ACPA-positive patients, disease activity was linked to MACE in RF-positive but not RF-negative ones (p for interaction=0.040). Conclusions Disease activity may better discriminate inflammation-driven cardiovascular risk in seronegative and double seropositive than single RF-positive or ACPA-positive patients. Risk protection through lowering disease activity may be serostatus dependent.
ID #1015 A murine model system for IDH-mutant 1p/19q-codeleted oligodendroglioma
Kundu, Ipsita, Toro, Nicolás , Mochizuki, Aaron, Cronk, James, Langhnoja, Jaldeep, Ayyagari, Rithvik, Reel, Sarah, Arounleut, Phonepasong, Esqueda, Luis Tron, Fuller, Christine , Viswanath, Pavithra, Heimberger, Amy B. , Horbinski, Craig, Phoenix, Timothy, Kundu, Ipsita, Mochizuki, Aaron Y. , Langhnoja, Jaldeep , Ayyagari, Rithvik V, Reel, Sarah Martin , Esqueda, Luis Tron , Viswanath, Pavithra , Heimberger, Amy B. , Horbinski, Craig , Phoenix, Timothy N.

Mayo Clinic

Neuro-Oncology Pediatrics | June 24, 2026 | Volume: 2 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuag026.446 Get It

Abstract Background Oligodendrogliomas were previously defined by histology, but since 2016, the WHO has integrated molecular signatures to create the entity of IDH-mutant 1p/19q-codeleted oligodendroglioma. These tumors harbor recurrent genetic alterations—including IDH mutations, CIC and FUBP1 loss-of-function mutations, and PI3K-activating mutations—that collectively define a genetic profile distinct from IDH-mutant astrocytoma and IDH wild-type glioblastoma. The paucity of faithful model systems has impeded progress in advancing mechanistic insights and therapeutic development for oligodendroglioma. Results To test whether recurrent mutations found in oligodendroglioma patients would drive tumor formation in mice, we utilized in utero electroporation to introduce combinations of gain- and loss-of-function mutations into the developing cortex. Initial tests that included expression of IDH-and PIK3CA-mutants with Cic and Fubp1 loss (termed Oligo) were non-tumorigenic but biased cells towards glial lineages. Introducing Cdkn2a-loss, which is normally suppressed by IDH-associated epigenetic changes in human tumors, to the Oligo combination (termed Oligo-Cdkn2a) resulted in fully penetrant tumor formation. Histopathological review showed the Oligo Cdkn2a-loss mouse model resembled grade II/III oligodendroglioma with rounded nuclei and open chromatin. If Trp53-loss is used (termed Oligo-Trp53) in place of Cdkn2a-loss, tumor histology shifts to a more astrocytic phenotype with angulated nuclei with denser chromatin, demonstrating a direct impact of Trp53-loss on histological features. Bulk RNA-sequencing verifies metabolic alterations driven by the presence of IDH-mutations in Oligo-Cdkn2a mouse models compared to an IDH wild-type GBM model. Single-cell transcriptional profiling shows that Oligo-Cdkn2a tumors contain an increased population of tumor cells that resemble more differentiated oligodendrocytes. Examination of the tumor immune microenvironment within Oligo-Cdkn2a and IDHWT GBM mouse models is being performed to determine changes in immune cell infiltration and transcriptional programs. Conclusion We have created, to our knowledge, the first murine model of IDH-mutant 1p/19q-codeleted oligodendroglioma that incorporates Cic loss. This immune-competent mouse model of IDH-mutant 1p/19q-codeleted oligodendroglioma offers a powerful new tool for interrogating tumor biology and evaluating preclinical therapeutic strategies.
Clinical Features of Palmoplantar Nonmelanoma Skin Cancers; a Multicenter Retrospective Study
Cumsky, Helen J.L., Smith, Sarah E. B. , Swanson, Leah A. , Ochoa, Shari, Ochoa, Shari A.

Mayo Clinic

Dermatologic Surgery | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dss.0000000000005240 | PMID 42335090 Get It

Emerging directions in tauopathy research
Wildsmith, Kristin R., Alladi, Suvarna, Bertucci, Taylor, Bowles, Kathryn R. , Boxer, Adam, Brummet, Jennifer, DeVos, Sarah L., Diaz, Kristophe , Duff, Karen, Duran‐Aniotz, Claudia, Farrell, Kurt, Fontana, Igor C., Franzmeier, Nicolai, Frost, Bess, Petrucelli, Leonard, Rexach, Jessica, Reyderman, Larisa, Rommel, Amy, Bohórquez, Sandra M. Sanabria, Schöll, Michael, Schneider, Anja, Silva, Rohan de , Snyder, Heather M. , VandeVrede, Lawren, Varga, Andrew W, Vogel, Jacob W., Yeh, Felix L. , Yoo, Andrew S., Carrillo, Maria C., Duff, Karen , Bertucci, Taylor , Mahinrad, Simin , Buée, Luc , Alladi, Suvarna , Boche, Delphine , DeVos, Sarah L. , Dreyer, Anna J. , Duran‐Aniotz, Claudia , Durrant, Claire S. , Farrell, Kurt , Fontana, Igor C. , Franzmeier, Nicolai , Frost, Bess , Horie, Kanta , Kaňovský, Petr , Kao, Aimee W. , Mahinrad, Simin , Malpetti, Maura , Morris, Huw R. , Palleis, Carla , Petrucelli, Leonard , Rexach, Jessica E. , Reyderman, Larisa, Rowe, James B. , Bohórquez, Sandra Sanabria , Sato, Chihiro , Schneider, Anja , VandeVrede, Lawren , Varga, Andrew W. , Vogel, Jacob W. , Yoo, Andrew S.J. , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | June 22, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71431 | PMID 42324487 Get It

Abstract The Tau Global Conference 2025, hosted by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation, convened international experts from academia, industry, government, and philanthropy to explore advances and challenges in tauopathy research. The meeting highlighted progress across tau biology, including emerging models of tau regulation, degradation, and propagation; advances in biomarker development for the diagnosis and staging of tauopathies; and evolving therapeutic strategies targeting diverse aspects of tau pathophysiology. Discussions also emphasized the importance of cross‐sector collaboration, and global initiatives to address disparities in tau research. This report synthesizes key insights from the conference and underscores the critical role of interdisciplinary, biomarker‐driven, and globally inclusive approaches in accelerating the translation of tau research into effective clinical applications.
Microglial SWELL1 deficiency drives male-specific seizure vulnerability but paradoxical neuroprotection through impaired phagocytosis
Barath, Abhijeet S. , Dheer, Aastha , Montier, Laura, Peshoff, Mekenzie M, Dale, Emily C., Goche, Flavia, Kleidonas, Dimitrios, Harris, Lauren, Jewanee, Sarah A., Bosco, Dale B. , Haruwaka, Koichiro , Sah, Rajan , Peshoff, Mekenzie , Dale, Emily, Peshoff, Mekenzie M, Goche, Flavia, Nguyen, Thanh Thanh L. , Akter, Mastura , Qi, Fangfang , Kleidonas, Dimitrios, Harris, Lauren, Jewanee, Sarah A., Umpierre, Anthony D. , Wu, Long‐Jun

Mayo Clinic

JCI Insight | June 21, 2026 | Volume: 11 | Issue: 12 | Pages: No page available

10.1172/jci.insight.197980 | PMID 42325092 Get It

The discovery of genes encoding the volume-regulated anion channel (VRAC) has enabled detailed exploration of its cell type–specific roles in the brain. LRRC8A (SWELL1) is the essential VRAC subunit. We observed seizure-induced, subunit-specific changes in microglial VRAC expression and investigated its function using conditional KO (cKO) of LRRC8A in microglia. SWELL1 cKO mice exhibited a male-specific increase in kainate-induced seizure severity, yet showed paradoxical neuroprotection against seizure-associated neuronal loss. Mechanistically, SWELL1 deletion led to a cell-autonomous reduction in microglial density and decreased release of VRAC-permeable neuroactive metabolites, including taurine, GABA, and glutamate in culture. Additionally, impaired phagocytic kinetics and reduced lysosomal biogenesis contributed to the observed neuroprotection. These findings reveal potentially novel roles for microglial VRAC in regulating seizure outcomes and microglia-neuron interactions.
Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre‐Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors
Chen, R, Master, Viraj, Mi, Lanyu , James, Sarah E., Moore, Cassandra, Bryce, Alan H., Tilburt, Jon C., Riaz, Irbaz B, Naqvi, Syed Arsalan Ahmed , Afzal, Umar, Cobran, Ewan K. , Asiri, Ibrahim M. , Cobran, Ewan K , Bryce, Alan H. , Tilburt, Jon C. , Beach, Steven R. H.

Mayo Clinic

Pharmacoepidemiology and Drug Safety | June 20, 2026 | Volume: 35 | Issue: 7 | Pages: No page available

10.1002/pds.70405 | PMID 42322109 Get It

ABSTRACT Background Men with castration‐resistant prostate cancer (CRPC) who have a pre‐existing history of cardiovascular disease (CVD) or other comorbidities are often excluded from clinical trials involving oral androgen receptor pathway inhibitors (ARPi). In this study, we compared all‐cause and prostate cancer‐specific mortality among CRPC patients, with and without a pre‐existing history of CVD, receiving ARPi compared to chemotherapy. Methods Men with CRPC were identified using the Surveillance, Epidemiology, and End Results‐Medicare Linked Database from 2004 to 2015. Patients were grouped into two analytical cohorts by drug use. Inverse probability treatment weights (IPTW)‐adjusted Cox models and Fine‐Gray subdistribution hazards models were used to evaluate associations between ARPi and chemotherapy, and between ENZ and AA for all‐cause mortality and cancer‐specific mortality separately. Results The study cohort included 1438 men with CRPC. Nearly 54.4% of patients had a pre‐existing history of CVD. Patients with a pre‐existing history of CVD had a higher incidence of all‐cause and prostate cancer‐specific mortality compared to patients without a history of CVD (all‐cause mortality: 69.7% vs. 59.3%, prostate cancer‐specific mortality: 56.0% vs. 49.5%, respectively). In the pre‐existing history of CVD cohort, the IPTW‐adjusted Cox model showed a significantly lower all‐cause mortality in patients who received APRi, enzalutamide, and abiraterone, versus chemotherapy (IPTW‐adjusted hazard ratio [AHR], 0.56; 95% Confidence Interval [CI], 0.48–0.64; p ‐value < 0.001). Further, the IPTW‐adjusted competing risk model showed significantly lower prostate cancer‐specific mortality in patients who received ARPi compared with those who received chemotherapy (IPTW‐AHR, 0.48; 95% CI, 0.41 to 0.57; p ‐value < 0.001). In the without pre‐existing history of CVD cohort, the adjusted Cox model showed significantly lower all‐cause mortality in patients who received APRi than those who received chemotherapy (IPTW‐AHR, 0.49; 95% CI, 0.41–0.60; p ‐value < 0.001). Whereas the IPTW‐adjusted competing risk model showed significantly lower prostate cancer‐specific mortality in patients who received ARPi compared with those who received chemotherapy (IPTW‐AHR, 0.52; 95% CI, 0.42–0.64; p ‐value < 0.001). Conclusion In this population‐based cohort of older men with castration‐resistant prostate cancer, treatment with oral androgen receptor pathway inhibitors was associated with lower estimated risks of all‐cause and prostate cancer–specific mortality compared with chemotherapy in patients with and without pre‐existing CVD. These findings add real‐world comparative effectiveness evidence for patient populations not well represented in randomized clinical trials; however, given the observational design and limitations of administrative data, residual confounding and unmeasured clinical differences may have influenced the results.